Ivacaftor withdrawal syndrome: A rare but potentially life-threatening consequence from a life-saving medication
Clofazimine has no influence on the blood concentrations of tezacaftor-ivacaftor in a patient with cystic fibrosis.
Defining constipation in patients with Cystic Fibrosis following criteria delineated by the European Society for Paediatric Gastroenterology Hepatology and Nutrition
Defining constipation in patients with Cystic Fibrosis following criteria delineated by the European Society for Paediatric Gastroenterology Hepatology and Nutrition
A summary of previously-published research looking at the length of treatment of acute infections and exacerbations in people with cystic fibrosis
There are two main types of problems with arteries in cystic fibrosis and existence of one or the other depends on pancreatic health
Testicular pain following initiation of elexacaftor/tezacaftor/ivacaftor in males with cystic fibrosis
Lung infection by Pseudomonas aeruginosa in children with cystic fibrosis: risk factors and impact on lung function
How changes in health insurance coverage for young children with CF can impact important health outcomes, such as lung function at 6 years of age
